(b)
according to the protocol of the clinical trial, the investigational medicinal products are used in accordance with the terms of the marketing authorisation; or the use of the investigational medicinal products is evidence-based and supported by published scientific evidence on the safety and efficacy of those investigational medicinal products in any of the Member States concerned; and
← art_2__para_2__point_3__point_a__text_1 · All articles · art_2__para_2__point_3__point_b__text_1 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.